SOHM Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has appointed Dr. Larissa Karnaoukhova as Vice President of Operations. Dr. Karnaoukhova brings significant credentials including a Ph.D. in Molecular Biology and an MBA, along with extensive experience in site operations management, sales, and business development. Her previous roles include Senior Director of Operations at Universal Sequencing Technology, where she managed manufacturing, quality control, and supply chain operations. At SOHM, she will focus on enhancing operational efficiency, leading QA/QC initiatives, FDA audits, process validations, and SOPs. The appointment aims to strengthen SOHM's operational capabilities and drive growth in the health sciences sector.
SOHM Inc. (OTC PINK:SHMN), azienda farmaceutica e biotecnologica, ha nominato la Dott.ssa Larissa Karnaoukhova Vicepresidente delle Operazioni. La Dott.ssa Karnaoukhova possiede importanti qualifiche, tra cui un dottorato in Biologia Molecolare e un MBA, oltre a una vasta esperienza nella gestione delle operazioni di sito, vendite e sviluppo commerciale. In precedenza 猫 stata Direttrice Senior delle Operazioni presso Universal Sequencing Technology, dove ha gestito la produzione, il controllo qualit脿 e le operazioni della catena di approvvigionamento. In SOHM si concentrer脿 sul miglioramento dell'efficienza operativa, guidando iniziative di QA/QC, audit FDA, convalide di processo e SOP. Questa nomina mira a rafforzare le capacit脿 operative di SOHM e a stimolare la crescita nel settore delle scienze della salute.
SOHM Inc. (OTC PINK:SHMN), una empresa farmac茅utica y biotecnol贸gica, ha nombrado a la Dra. Larissa Karnaoukhova como Vicepresidenta de Operaciones. La Dra. Karnaoukhova aporta importantes credenciales, incluyendo un doctorado en Biolog铆a Molecular y un MBA, junto con amplia experiencia en gesti贸n de operaciones de sitio, ventas y desarrollo comercial. Anteriormente fue Directora Senior de Operaciones en Universal Sequencing Technology, donde gestion贸 manufactura, control de calidad y operaciones de la cadena de suministro. En SOHM, se enfocar谩 en mejorar la eficiencia operativa, liderando iniciativas de QA/QC, auditor铆as FDA, validaciones de procesos y SOP. Este nombramiento busca fortalecer las capacidades operativas de SOHM y fomentar el crecimiento en el sector de ciencias de la salud.
SOHM Inc. (OTC PINK:SHMN), une entreprise pharmaceutique et biotechnologique, a nomm茅 la Dre Larissa Karnaoukhova Vice-Pr茅sidente des Op茅rations. La Dre Karnaoukhova poss猫de des qualifications importantes, notamment un doctorat en biologie mol茅culaire et un MBA, ainsi qu'une vaste exp茅rience en gestion des op茅rations sur site, ventes et d茅veloppement commercial. Elle a pr茅c茅demment occup茅 le poste de Directrice Senior des Op茅rations chez Universal Sequencing Technology, o霉 elle g茅rait la production, le contr么le qualit茅 et les op茅rations de la cha卯ne d'approvisionnement. Chez SOHM, elle se concentrera sur l'am茅lioration de l'efficacit茅 op茅rationnelle, la direction des initiatives QA/QC, les audits FDA, les validations de processus et les proc茅dures op茅ratoires standard (SOP). Cette nomination vise 脿 renforcer les capacit茅s op茅rationnelles de SOHM et 脿 stimuler la croissance dans le secteur des sciences de la sant茅.
SOHM Inc. (OTC PINK:SHMN), ein Pharma- und Biotechnologieunternehmen, hat Dr. Larissa Karnaoukhova zur Vice President of Operations ernannt. Dr. Karnaoukhova bringt bedeutende Qualifikationen mit, darunter einen Ph.D. in Molekularbiologie und einen MBA, sowie umfangreiche Erfahrung im Standortbetriebsmanagement, Vertrieb und Gesch盲ftsentwicklung. Zuvor war sie Senior Director of Operations bei Universal Sequencing Technology, wo sie die Fertigung, Qualit盲tskontrolle und Lieferkettenprozesse leitete. Bei SOHM wird sie sich auf die Steigerung der betrieblichen Effizienz konzentrieren, QA/QC-Initiativen f眉hren, FDA-Audits, Prozessvalidierungen und SOPs leiten. Die Ernennung zielt darauf ab, die operativen F盲higkeiten von SOHM zu st盲rken und das Wachstum im Gesundheitswissenschaftssektor voranzutreiben.
Positive
Appointment of highly qualified executive with Ph.D. in Molecular Biology and MBA
Strong operational experience in regulated industries including manufacturing and quality control
Expertise in FDA audits, process validations, and quality initiatives which could improve regulatory compliance
Negative
None.
CHINO HILLS, CA / / June 11, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, health and wellness solutions, proudly announces the appointment of Dr. Larissa Karnaoukhova, Ph.D, MBA, as Vice President of Operations. With extensive experience in site operations management, sales, and business development within highly regulated industries, Larissa will play a pivotal role in enhancing operational efficiency and driving strategic initiatives at SOHM Inc.
David Aguilar, COO of SOHM Inc., warmly welcomes Larissa to the leadership team. "Larissa brings a wealth of expertise and a proven track record in managing complex operations and achieving key performance indicators. Her dynamic leadership style and commitment to excellence align perfectly with our mission to deliver high-quality products and services to our clients," Aguilar stated.
Larissa has held prominent roles, including Senior Director of Operations at Universal Sequencing Technology, where she successfully oversaw manufacturing, quality control, and supply chain management. Her background also includes significant achievements in project management, customer engagement, and quality assurance across various organizations, including AutoGenomics and LumiraDx, Nucleus Biologics and Invitrogen/Life Technologies. At SOHM, she will lead in further development of QA/QC, FDA audits, process validations, SOPs and other quality initiatives.
"I am excited to join SOHM Inc. and collaborate with a talented team dedicated to innovation and quality," said Larissa. "Together, we will strive to enhance our operational capabilities, improve customer satisfaction, and drive the company's growth in the health sciences sector."
Her academic credentials, including an MBA and a Ph.D. in Molecular Biology, complement her extensive professional background, providing a strong foundation for her new role. With her strategic mindset and technical expertise, Larissa is set to lead SOHM's operations into a new era of efficiency and quality.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted solutions for gene editing. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc.
View the original on ACCESS Newswire
FAQ
Who is the new Vice President of Operations at SOHM Inc. (SHMN)?
Dr. Larissa Karnaoukhova, who holds a Ph.D. in Molecular Biology and an MBA, has been appointed as the new Vice President of Operations at SOHM Inc.
What are Dr. Karnaoukhova's responsibilities at SOHM (SHMN)?
She will lead QA/QC initiatives, FDA audits, process validations, SOPs, and focus on enhancing operational efficiency and driving strategic initiatives.
What is Dr. Karnaoukhova's previous work experience before joining SOHM (SHMN)?
She previously served as Senior Director of Operations at Universal Sequencing Technology and held positions at AutoGenomics, LumiraDx, Nucleus Biologics, and Invitrogen/Life Technologies.
What type of company is SOHM Inc. (SHMN)?
SOHM Inc. is a pharmaceutical and biotechnology company that specializes in generic drugs, gene-editing tools, and health and wellness solutions.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
